Crossed from claiming to demonstrating: management marks its own before/after line with repeated, recent proof
The model's full reasoning — Q3 2022 call → NOWe need to determine if management conveys a recent crossing from claiming to demonstrating a capability, with repeated real events, and management drawing the before/after contrast. The transcript discusses CUE-101 and CUE-102. Key points: CUE-101 monotherapy and combination data presented at SITC. Management says "data bolsters our belief" and "positions us well" but also says "we are now very well positioned" etc. However, the question asks if they crossed from claiming to demonstrating something. They have clinical data, but is it a capability? They have demonstrated antitumor efficacy, survival benefit, etc. But is this a "capability" that was previously a promise? They have been developing this for a while. The question specifically: "management convey that the company has RECENTLY CROSSED FROM CLAIMING SOMETHING TO DEMONSTRATING IT — that a capability, offering, or way of doing business which until recently existed mainly as a promise, plan, or early attempt for THIS company is now something the company has actually done, and done MORE THAN ONCE, in the recent period — with management itself drawing the before-versus-now contrast?" Look for management's own words contrasting before and after. For example, Anish says "we believe, as supported by our clinical data that this approach is differentiated" - that's not a crossing. Dan says "The data bolsters our belief" - not a crossing. They talk about "clinical proof-of-concept" and "derisking" - but is that a crossing? They say "we have observed" etc. But do they explicitly say "previously we only claimed, now we have demonstrated"? Not exactly. They do say "The recent data presented at SITC positions us well" - that's not a before/after contrast. Perhaps the closest is about CUE-102: "we did not need to perform any additional IND-enabling toxicology studies and were allowed to start the CUE-102 trial at 1 mg/kg dose" - that's a regulatory advantage, not a capability demonstration. The question requires management drawing a before/after line. I don't see explicit "we used to claim, now we demonstrate" language. They are still in clinical trials, reporting data, but they are not saying "we have crossed from promise to proof" in a clear way. They are presenting data as encouraging, but not claiming a definitive crossing. Also, the after-side must be repeated real events.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| CNXC | Concentrix Corporation | Q1 2022 | 2022-03-30 | B |
| EXP | Eagle Materials Inc. | Q3 2022 | 2022-01-27 | B |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| LOW | Lowe's Companies, Inc. | Q3 2021 | 2021-11-17 | B+ |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| SXC | SunCoke Energy, Inc. | Q3 2021 | 2021-11-01 | A |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| FOSL | Fossil Group, Inc. | Q1 2018 | 2018-05-08 | C |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
DXCM · Q4 2023 → YESThe question is about whether management conveys that the company has recently crossed from claiming something to demonstrating it. YES The transcript shows management drawing a clear before/after contrast on the Malaysia manufacturing facility: previously they relied on established US facilities, but mid-year they opened a new site and are now ramping production with yields matching the US ones—real, repeated activity rather than a single event or plan. This is framed as 2023 being transformational, with the new capability already contributing to results and positioned for further scaling ahead. The primary-care expansion also fits as a demonstrated shift from long-term investment to immediate results (70% of new scripts), but the manufacturing crossing is the clearest match to the criteria.
LC · Q4 2021 → YESThe question is about whether management conveys that the company has recently crossed from claiming something to demonstrating it. YES The transcript shows management drawing a clear before/after line: Scott Sanborn describes closing 2021 in the strongest position after executing a strategy laid out in February, creating America's first digital marketplace bank; Tom Casey states the radical transformation over the last year is now complete as promised, contrasting it with 2019 4Q revenue and net income levels to highlight the fundamental change. The after-side is real and repeated—record revenue, doubled economics, NII recurring stream, multiple quarters of strong performance—backed by actual bank operations and deliveries.
KTB · Q3 2021 → YESThe question is about whether management conveys that the company has recently crossed from claiming something to demonstrating it. YES Management draws its own before/after line in Scott Baxter’s opening remarks: “we are doing things with both the Wrangler and Lee brands that we have simply never done before,” directly contrasting past practice with the current reality of new marketing campaigns (Lee launched October, Wrangler September). The after-side is 1) real and recent (Q3 results show 50 % growth in U.S. outdoor and 60 % growth in work wear versus 2019 baselines) and 2) repeated across multiple categories and brands, confirming the capability is now operating rather than a one-off event.